Radiographic progression-free survival in the ACIS trial for prostate cancer reply

被引：0
|
作者：
Saad, Fred [1 ]
De Porre, Peter [2 ]
Brookman-May, Sabine [3 ,4 ]
Li, Jinhui [5 ]
McCarthy, Sharon A. [6 ]
Rathkopf, Dana E. [7 ,8 ]
机构：
[1] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[2] Janssen Res & Dev, Beerse, Belgium
[3] Janssen Res & Dev, Los Angeles, CA USA
[4] Ludwig Maximilians Univ Munchen, Munich, Germany
[5] Janssen Res & Dev, San Diego, CA USA
[6] Janssen Res & Dev, Raritan, NJ USA
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[8] Weill Cornell Med, New York, NY USA
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E5 / E6
页数：2
相关论文
共 50 条
  • [1] Radiographic progression-free survival in the ACIS trial for prostate cancer
    Tannock, Ian F.
    Booth, Christopher M.
    Gyawali, Bishal
    Joshua, Anthony M.
    LANCET ONCOLOGY, 2022, 23 (01): : E4 - E4
  • [2] Prostate cancer: Validating radiographic progression-free survival
    Thoma C.
    Nature Reviews Urology, 2018, 15 (5) : 263 - 263
  • [3] Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Halabi, Susan
    Roy, Akash
    Rydzewska, Larysa
    Guo, Siyuan
    Godolphin, Peter
    Hussain, Maha
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael A.
    Smith, Matthew R.
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    James, Nick
    Buyse, Marc E.
    Tierney, Jayne F.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09)
  • [4] Progression-free survival in the ICON8 trial reply
    James, Elizabeth C.
    McNeish, Iain A.
    Cook, Adrian D.
    Kaplan, Richard
    Clamp, Andrew R.
    LANCET, 2020, 396 (10253): : 757 - 757
  • [5] MRI radiomics predicts progression-free survival in prostate cancer
    Jia, Yushan
    Quan, Shuai
    Ren, Jialiang
    Wu, Hui
    Liu, Aishi
    Gao, Yang
    Hao, Fene
    Yang, Zhenxing
    Zhang, Tong
    Hu, He
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Rucaparib extends progression-free survival in metastatic prostate cancer
    Franke, Katharina
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (21) : 1341 - 1341
  • [7] Estimation of Progression-Free Survival in the Randomized Discontinuation Trial Design Reply
    Nosov, Dmitry A.
    Strahs, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : 814 - 815
  • [8] Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.
    Halabi, Susan
    Roy, Akash
    Yang, Qian
    Xie, Wanling
    Kelly, William Kevin
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Radiographic progression-free survival (rPFS) and time to radiographic progression (TTrP) as surrogate endpoints in docetaxel-naive metastatic castrate resistant prostate cancer (mCRPC): A pooled analysis of COU-AA-302 and ACIS.
    Roy, Soumyajit
    Sun, Yilun
    Spratt, Daniel Eidelberg
    Morgan, Scott C.
    Kim, Thomas
    Malone, Julia
    Wallis, Christopher J. D.
    Kishan, Amar Upadhyaya
    Saad, Fred
    Malone, Shawn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer The PREVAIL Randomized Clinical Trial
    Rathkopf, Dana E.
    Beer, Tomasz M.
    Loriot, Yohann
    Higano, Celestia S.
    Armstrong, Andrew J.
    Sternberg, Cora N.
    de Bono, Johann S.
    Tombal, Bertrand
    Parli, Teresa
    Bhattacharya, Suman
    De Phung
    Krivoshik, Andrew
    Scher, Howard I.
    Morris, Michael J.
    JAMA ONCOLOGY, 2018, 4 (05) : 694 - 701
12345